Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 65 publications.

Liang Y, Salomonsen R, Colosia A, Nelsen SH, Khan S, Sandelin M. Interventions to improve adherence and persistence to oral medication: a targeted literature review. Poster to be given at the ISPOR 2025; May 14, 2025. Montréal, Canada.

Bektas M, Bell T, Khan S, Tumminello B, Fernandez MM, Heyes C, Oton AB. Desmoid tumors: a comprehensive review. Adv Ther. 2023 Sep;40(9):3697-722. doi: 10.1007/s12325-023-02592-0.

Fernandez MM, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Disease and economic burden of surgery in desmoid tumors: a review. Expert Rev Pharmacoecon Outcomes Res. 2023 Jul;23(6):607-18. doi: 10.1080/14737167.2023.2203915

Fernandez M, Bell T, Tumminello B, Khan S, Zhou S, Oton AB. Burden of surgery in desmoid tumors. Poster presented at the ISPOR 2023 Conference; May 7, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S22. doi: 10.1016/j.jval.2023.03.117

Fernandez M, Bell TJ, Khan S, Tumminello B, Bektas M, Heyes CE, Oton AB. Burden of illness of desmoid tumors. Poster presented at the 2022 CTOS Annual Meeting; November 16, 2022. Vancouver, Canada. Previously presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting.

Colosia A, Njue A, Bajwa Z, Dragon E, Robinson RL, Sheffield KM, Thakkar S, Richeimer SH. The burden of metastatic cancer-induced bone pain: a narrative review. J Pain Res. 2022 Oct 25;2022(15):3399-412. doi: 10.2147/JPR.S371337

Bell T, Fernandez M, Khan S, Tumminello B, Bektas M, Heyes CE, Oton AB. Patient burden of illness associated with desmoid tumors. Poster presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting; September 24, 2022. Philadelphia, PA.

Salas M, Mordin M, Castro C, Islam Z, Tu N, Hackshaw MD. Health-related quality of life in women with breast cancer: a review of measures. BMC Cancer. 2022 Jan 15;22(1):66. doi: 10.1186/s12885-021-09157-w

Noon K, Costello J, Krieger T, Rothwell B, Pearson I. Utility weight considerations in NICE immune checkpoint inhibitor oncology appraisals. Poster presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec; 23(S2).

Huang L, Masaquel C, Mauskopf J. Targeted review to understand the evolution of national meningococcal vaccination recommendations in four countries. Poster presented at the 2020 European Society for Paediatric Infectious Diseases (ESPID) Virtual Meeting; October 26, 2020.

Castro C, Mordin M, Islam Z, Tu N, Hackshaw MD, Salas M. A review of non-disease specific health-related quality of life measures with reliability and validity evidence in patients with breast cancer. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S81.

Ramasamy K, Dhanasiri S, Thom H, Buchanan V, Robinson S, D'Souza VK, Weisel K. Relative efficacy of treatment options in transplant-ineligible newly diagnosed multiple myeloma: results from a systematic literature review and network meta-analysis. Leuk Lymphoma. 2020 Mar;61(3):668-79. doi: 10.1080/10428194.2019.1683736

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer. Lung Cancer. 2019 Feb 8;2019:11-20. doi: 10.2147/LCTT.S179349

Masaquel C, Rothwell B, Bhaila R, Copley-Merriman C, Wolowacz S, Aguiar-Ibanez R, Patel N, Liu FX. A systematic review of utility estimates in melanoma in the adjuvant setting. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Copley-Merriman C, Stevinson K, Liu FX, Wang J, Mauskopf J, Zimovetz EA, Chmielowski B. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review. Medicine. 2018 Aug;97(31):e11736. doi: 10.1097/MD.0000000000011736

Barrows SM, Cai B, Copley-Merriman C, Wright KR, Castro CV, Soufi-Mahjoubi R. Systematic literature review of the antitumor effect of octreotide in neuroendocrine tumors. World J Meta-Anal. 2018 Jun 28;6(2):9-20.

Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET. Systematic Literature Review (SLR) of sequencing of Anaplastic Lymphoma Kinase (ALK) inhibitors in ALK-Positive Non-Small Cell Lung Cancer (NSCLC). Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S49-50. doi: 10.1016/j.jval.2018.04.291

Masaquel C, Hurley D, Barnett B, Krieger T, Pearson I, Copley-Merriman C, Kaye JA, Moy B. Clinical and economic burden of HER2-positive breast cancer recurrence in the US: a literature review. Poster presented at the 2017 San Antonio Breast Cancer Symposium; December 7, 2017. San Antonio, TX.

Barrows SM, Cai B, Wright K, Castro CV, Kaye JA, Copley-Merriman C, Soufi-Mahjoubi R. Systematic literature review of octreotide's antitumor effects in neuroendocrine tumors. Poster presented at the 2017 North American Neuroendocrine Tumor Society Annual Symposium; October 19, 2017. Philadelphia, PA.

Boysen M, Tyas D, Ling C, Wolowacz S. The new NICE cancer drugs fund technology appraisal process: your questions answered. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.

Taylor S, Demeyin (Nuabor) W, Muls A, Ferguson C, Farnell DJ, Cohen D, Andreyev J, Green J, Smith L, Ahmedzai S, Pickett S, Nelson A, Staffurth J. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. BMJ Open. 2016 Oct 3;6(10):e011773. doi: 10.1136/bmjopen-2016-011773

Colosia A, Khan S, Hackshaw MD, Oglesby A, Kaye JA, Skolnik JM. A systematic literature review of adverse events associated with systemic treatments used in advanced soft tissue sarcoma. Sarcoma. 2016 Jul 19;2016:3597609. doi: 10.1155/2016/3597609

Masaquel C, Jerusalem G, Copley-Merriman K, Ray D, Higuchi K, Caceres V. Economic burden of advanced breast cancer. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A146.

Khan S, Zimovetz E, Healey P, Copley-Merriman K. Biologics in ulcerative colitis (UC): treatment guidelines, health technology assessments (HTA). Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. [abstract] Value Health. 2015 Nov; 18(7):A633.

Police RL, Trask PC, Wang J, Olivares R, Khan SB, Abbe A, Colosia AD, Njue AI, Sherrill EH, Ruiz-Soto R, Kaye JA, Hamadani M. Randomized controlled trials in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):199-207. doi: 10.1016/j.clml.2014.09.008

Njue A, Colosia A, Trask PC, Olivares R, Khan S, Police R, Abbe A, Wang J, Kaye JA, Ruiz-Soto R, Awan F. Clinical efficacy and safety in relapsed/refractory mantle cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):1-12. doi: 10.1016/j.clml.2014.03.006

Colosia A, Njue A, Trask PC, Olivares R, Khan S, Abbe A, Police R, Wang J, Ruiz-Soto R, Kaye JA, Awan F. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):343-55. doi: 10.1016/j.clml.2014.02.012

Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.

Xu J, Evans J, Coon C, Copley-Merriman K, Su Y. Measuring patient-reported outcomes in advanced gastric cancer. Ecancermedicalscience. 2013;7:351. doi: 10.3332/ecancer.2013.351.

Braun L, Sood V, Hogue S, Lieberman B, Copley-Merriman C. High burden and unmet patient needs in chronic kidney disease. Int J Nephrol Renovasc Dis. 2012 Dec 1;5:151-63.

Kiladjian JJ, Gisslinger H, Passamonti F, Neiderwieser D, Medelson E, Sirulnik LA, Copley-Merriman K, Zhou X. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasms; October 4, 2012. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Colosia AD, Peltz G, Pohl G, Liu E, Copley-Merriman K, Khan S, Kaye JA. A review and characterization of the various perceptions of quality cancer care. Cancer. 2011 Mar 1;117(5):884-96.

Khan SB, Peltz G, Pohl G, Liu E, Copley-Merriman K, Colosia AD. Impact of patient/provider communications on quality of care for cancer. Poster presented at the 3rd Conference of the American Association for Cancer Research; October 2010.

Copley-Merriman K, Peltz G, Pohl G, Liu E, Kaye JA. Impact of race/ethnicity and health insurance status on quality of care for cancer. Poster presented at the Annual Meeting of the American Society of Clinical Oncology; June 2010.

Colosia AD, Khan SB, Peltz G, Pohl G, Liu E, Kaye JA. Electronic medical records: quality cancer care and cost-effectiveness. Poster presented at the 2010 ISPOR 15th Annual International Meeting; May 26, 2010. [abstract] Value Health. 2010 May; 13(3):A52.

Jorgensen E, Stinson A, Shan L, Yang J, Gietl D, Albino AP. Cigarette smoke induces endoplasmic reticulum stress and the unfolded protein response in normal and malignant human lung cells. BMC Cancer. 2008 Aug 11;8:229. doi: 10.1186/1471-2407-8-229

Abetz L, Coombs JH, Keininger DL, Earle CC, Wade C, Bury-Maynard D, Copley-Merriman K, Hsu MA. Development of the cancer chemotherapy satisfaction questionnaire (CCSQ): item generation and content validity testing. Value Health. 2005 Nov;8(Suppl 1):S41-53.

Cella D, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Heyes A, Ochs JS, Wolf MK, Kay AC, Kris MG, Natale RB. Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol. 2005 May 1;23(13):2946-54.

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional assessment of cancer therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr 1;90(3):295-8.

Schmidt RA, Ackerman SJ, Newstead GM, Quam JP, Mordin MM, Anastassopoulos K, Nishikawa RM. Comparative feature analysis of computed radiography for mammography (CRM) soft copy display vs. crm hard copy film: an observer performance study. Poster presented at the 90th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2004.

Heyes A. Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Semin Oncol. 2004 Jun 1;31(Suppl. 9):16-22.

Copley-Merriman K, Jackson J, Boyer JG, Cappelleri J, DeMarinis R, DiCesare J. Industry perspective regarding outcomes research in oncology. New York: NY. Cambridge University Press; 2004. p.623-38.

Quam JP, Ackerman SJ, Mordin MM, Bassett LW. Conspicuity and characterization of findings on computed radiography for mammography vs. screen-film mammography: results from a prospective clinical trial. Poster presented at the 89th Scientific Assembly and Annual Meeting of the Radiology Society of North America; November 2003.

Dorazio P, Keininger DL, Abetz L, Coombs JH, Copley-Merriman K, Bury-Maynard DP, Hsu MA. Comparing patient and nurse perspectives on cancer treatment: results from a qualitative study. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; September 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 Sep; 22:778.

Douillard JY, Cella D, Natale R, Lynch TL, Lee C, Carbone D, Kay A, Wolf M M, Heyes AE, Ward J. Clinically meaningful improvement in disease-related symptoms by 'gefitinib' (Iressa, ZD1839) in patients with advanced non-small cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival. Presented at the European Cancer Conference 12; September 2003; September 2003. Copenhagen, Denmark.

LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.

Coombs JH, Abetz L, Keininger DL, Earle CC, Copley-Merriman K, Hsu M-A, Bury-Maynard DP. Development of the Cancer Chemotherapy Satisfaction Questionnaire (CCSQ): part I: item-generation and content validity testing. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:545.

Osoba D, Hsu M-A, Copley-Merriman K, Johnson FR, Hauber AB, Coombs J. Cancer patients' preferences for health-related quality of life (HRQOL) domains during treatment. Poster presented at the 2003 Annual Meeting of the American Society of Clinical Oncology; May 2003.

Cella D, Natale R, Lynch T T, Lee C, Carbone D, Douillard JY, Kay A, Wolf M, Heyes AE, Ward J. Disease-related symptoms in advanced nsclc as measured by the lung cancer subscale (LCS) of the fact-l questionnaire: clinically meaningful improvement with gefitinib (Iressa, ZD1839). Presented at the American Society of Clinical Oncology; May 2003. Chicago, IL.

Clark M, Copley-Merriman K, Coombs JH, Von Pawel J, Koschel G, Pauer LR. Patient reported outcomes (symptoms, functioning, and quality of life [QOL]) in a randomized Phase II study of CI-994 plus carboplatin and paclitaxel (C/T) vs placebo (PBO) plus C/T in the first-line treatment of patients with advanced nonsmall cell lung cancer (NSCLC). Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology; May 2003. Chicago, IL. [abstract] American Society Of Clinical Oncology Meeting Proceedings. 2003 May; 22:687.